Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Research May Mean Fewer Side Effects For Women With Bone Metastases

New findings may pave the way for people with stage IV breast cancer in the bones to receive bone-strengthening treatment less often. These results could mean decreased risk of side effects.

ASCO Issues Guidelines for Preventing and Managing Neuropathy, Fatigue, Depression and Anxiety

The American Society of Clinical Oncology published 3 new guidelines for physicians so they may better help people prevent or manage neuropathy, fatigue, depression and anxiety. These common cancer side effects may linger long after treatment.

The guidelines are based on ASCO’s review of published research and its assessment of risks and benefits for treatments. They are the first in a planned series of guidelines for caring for people who have any type of cancer. Here’s a look at each side effect and the new guideline for each:

Medicine Given with Chemotherapy May Protect Fertility

Before and during chemotherapy, giving premenopausal women with estrogen receptor-negative (ER-) breast cancer the medicine goserelin (Zoladex) improved their ability to become pregnant several years after treatment and to deliver healthy babies.

Breast Cancer Response to Pre-Surgery Chemotherapy May Suggest its Benefit in Long-term

Showing no sign of invasive cancer in the breast or nearby lymph nodes after treatment with pre-surgery chemotherapy may lead to longer survival, an analysis of 12 international studies suggests. This was most true for those with hormone receptor-negative, HR-negative, breast cancers.

ASCO Issues First Guidelines for Metastatic HER2-positive Breast Cancer

To help doctors recommend treatment options based on research evidence and expert consensus, the American Society of Clinical Oncology released its first guidelines on treating metastatic HER2-positive breast cancer.

ASCO issued two clinical practice guidelines for this breast cancer type. One advises on systemic (whole body) therapies for HER2-positive breast cancer that has advanced outside of the breast, other than to the brain. The other recommends specifics on treating brain metastases.

ASCO Reports on Early-Stage Breast Cancers

LBBC highlights two studies reported on the last day of the annual meeting of the American Society of Clinical Oncology: GeparSixto, which looked at the impact of adding a platinum chemotherapy to standard medicines given before surgery to people with triple-negative breast cancer and a family history of breast or ovarian cancer; and an analysis of the PAM50 genomic assay as a tool to help people with early-stage breast cancer make decisions about mastectomy versus lumpectomy and radiation. 

Targeted Therapies Heat up Oncology Meeting

Sunday reports from the 50th annual meeting of the American Society of Clinical Oncology focused on using aromatase inhibitors in premenopausal women with early-stage, estrogen-positive breast cancer and on a negative study of lapatinib for HER2-positive early-stage disease. 

ASCO Studies Focus on Premenopausal Women

Researchers announced findings from breast cancer studies during Saturday’s sessions of the 50th Annual Meeting of the American Society of Clinical Oncology, in Chicago. Today's reports focus on obesity and risk of recurrence in pre- and peri-menopausal women; preserving fertility in young women taking chemotherapy; and the future of bevacizumab (Avastin) in breast cancer. 

Should Low Estrogen Receptor Status Be Considered Positive?

Breast cancers with a low level of estrogen receptor positivity – only 1 to 9 percent of tumor cells being positive – is more similar to ER-negative disease than to breast cancer with ER positivity of 10 percent or greater, according to a recent study. 

African-Americans More Likely to Stop Working During Early Breast Cancer Treatment, Study Suggests

African-American women were more likely to stop working during the first 2 months of breast cancer treatment compared with non-Hispanic white peers, an analysis found. The study, published in Journal of Cancer Survivorship, assessed racial differences in quality of life and employment after breast cancer diagnosis.